NASDAQ:KTRA Kintara Therapeutics (KTRA) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free KTRA Stock Alerts $0.15 -0.01 (-3.77%) (As of 01:17 PM ET) Add Compare Share Share Today's Range$0.15▼$0.1650-Day Range$0.08▼$0.1652-Week Range$0.08▼$5.60Volume1.50 million shsAverage Volume12.82 million shsMarket Capitalization$5.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Kintara Therapeutics alerts: Email Address Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Kintara Therapeutics Stock (NASDAQ:KTRA)Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.Read More KTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTRA Stock News HeadlinesMay 3, 2024 | nasdaq.comKintara Therapeutics, Inc. Common Stock (KTRA)May 2, 2024 | americanbankingnews.comKintara Therapeutics (NASDAQ:KTRA) Stock Price Down 4.7%May 8, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRAApril 10, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, KTRAApril 9, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRAApril 5, 2024 | businesswire.comKINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRAApril 5, 2024 | finance.yahoo.comAPhA and CDC select Community of Practice Teams to advance health equity and prevent heart disease and strokeMay 8, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 3, 2024 | markets.businessinsider.comCrude Oil Moves Higher; ISM Services PMI Falls In MarchApril 3, 2024 | msn.comWhy Kintara Therapeutics Shares Are Gaining TodayApril 3, 2024 | stockhouse.comKTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to ShareholdersApril 3, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURAApril 3, 2024 | investorplace.comWhy Is Kintara Therapeutics (KTRA) Stock Up 103% Today?April 3, 2024 | marketwatch.comKintara Therapeutics Sets Reverse Merger With TuHURA BiosciencesApril 3, 2024 | markets.businessinsider.comKintara Therapeutics To Merge Into TuHURA BiosciencesApril 3, 2024 | finance.yahoo.comKintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementMarch 27, 2024 | finance.yahoo.comKintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabMarch 27, 2024 | prnewswire.comKintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabMarch 15, 2024 | nasdaq.comKintara Therapeutics Bounces BackFebruary 21, 2024 | uk.investing.comKintara Therapeutics Inc (KTRA)February 20, 2024 | uk.investing.comMyMD Pharmaceuticals Inc (0A8D)February 14, 2024 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateFebruary 14, 2024 | prnewswire.comKintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateFebruary 12, 2024 | finance.yahoo.comKintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerFebruary 1, 2024 | msn.comPanbela Therapeutics closes ~$9M public offering of sharesDecember 7, 2023 | markets.businessinsider.comKintara Announces Review Of Strategic Alternatives To Maximize Stockholder ValueSee More Headlines Receive KTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/08/2024Next Earnings (Estimated)5/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTRA CUSIPN/A CIK1498382 Webwww.kintara.com Phone(858) 350-4364Fax604-608-5685Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,650,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-305.69% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.86) per share Price / Book-0.03Miscellaneous Outstanding Shares39,040,000Free Float37,152,000Market Cap$6.00 million OptionableNot Optionable Beta0.42 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jeffrey A. Bacha B.Sc. (Age 56)M.B.A., Founder Mr. Greg A. JohnsonActing Head of OperationsKey CompetitorsOragenicsNYSE:OGENXenetic BiosciencesNASDAQ:XBIOHoth TherapeuticsNASDAQ:HOTHAdial PharmaceuticalsNASDAQ:ADILYumanity TherapeuticsNASDAQ:YMTXView All Competitors KTRA Stock Analysis - Frequently Asked Questions Should I buy or sell Kintara Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KTRA shares. View KTRA analyst ratings or view top-rated stocks. How have KTRA shares performed in 2024? Kintara Therapeutics' stock was trading at $0.1696 on January 1st, 2024. Since then, KTRA shares have decreased by 10.3% and is now trading at $0.1521. View the best growth stocks for 2024 here. Are investors shorting Kintara Therapeutics? Kintara Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 658,900 shares, a decrease of 70.1% from the March 15th total of 2,200,000 shares. Based on an average daily trading volume, of 14,420,000 shares, the days-to-cover ratio is currently 0.0 days. View Kintara Therapeutics' Short Interest. When is Kintara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KTRA earnings forecast. How were Kintara Therapeutics' earnings last quarter? Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.24) earnings per share for the quarter. When did Kintara Therapeutics' stock split? Kintara Therapeutics shares reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Kintara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). How do I buy shares of Kintara Therapeutics? Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KTRA) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
